BioSpace News Archive

The state Department of Public Health will hold a public hearing on Wednesday, October 23 regarding Southcoast Hospitals Group’s proposed closure of the maternity unit at Tobey Hospital — a proposal that has drawn strong opposition from both current and past patients of the unit, as well as local nurses, obstetricians, midwives, women’s health advocates, and elected officials.

Venarum Medical, LLC today announced receipt of a mentorship grant in further support of its awarded Phase II SBIR Grant “EVVS: EndoVenous Valve System” currently underway.

Centerline Biomedical, Inc., announces that Phil Rackliffe has been appointed to lead Centerline Biomedical and its recently FDA Cleared Intra-Operative Positioning System (IOPS) with augmented reality 3D guidance, navigation, and control (3D-GNC).

Align Technology, Inc. announced an agreement with the New England Patriots, making the Invisalign brand the official smile of the New England Patriots football team and a sponsor of the New England Revolution professional soccer club.

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate Pharma” or the “Company”), today announced the closing of its previously announced global offering to specified categories of investors of an aggregate of 14,375,000 new ordinary shares,

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Mylan N.V. (NASDAQ: MYL) (“Mylan”) today announced that data from studies of YUPELRI® (revefenacin) inhalation solution will be presented at CHEST 2019, the annual meeting of the American College of Chest Physicians, on Oct. 22 in New Orleans, LA.

Kala Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

The webcast will be archived for approximately 30 days following the event.

The show can also be viewed on You Tube after the LIVE broadcast.

AmerisourceBergen, Cardinal Health and McKesson announced this morning that they have agreed to a $215 million settlement with two Ohio counties, Cuyahoga and Summit, in the first track of the multi-district opioid litigation.